What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cardiology
Yoshinobu Onuma mainly focuses on Stent, Surgery, Internal medicine, Cardiology and Coronary artery disease.
His work deals with themes such as Clinical endpoint, Everolimus and Mace, which intersect with Stent.
Internal medicine is represented through his Percutaneous coronary intervention and Myocardial infarction research.
His study looks at the relationship between Myocardial infarction and topics such as Hazard ratio, which overlap with EuroSCORE.
Yoshinobu Onuma combines subjects such as Percutaneous and Prospective cohort study with his study of Cardiology.
As a member of one scientific family, he mostly works in the field of Coronary artery disease, focusing on Fractional flow reserve and, on occasion, Computed tomography angiography, Cardiothoracic surgery, Hyperaemia and Receiver operating characteristic.
His most cited work include:
- A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods (686 citations)
- A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial (597 citations)
- Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II (488 citations)
What are the main themes of his work throughout his whole career to date?
Yoshinobu Onuma mainly investigates Internal medicine, Cardiology, Percutaneous coronary intervention, Surgery and Stent.
His Internal medicine study focuses mostly on Myocardial infarction, Coronary artery disease, Revascularization, Drug-eluting stent and Hazard ratio.
His work on Angioplasty, Artery and Regurgitation is typically connected to In patient as part of general Cardiology study, connecting several disciplines of science.
His work is dedicated to discovering how Percutaneous coronary intervention, Conventional PCI are connected with Percutaneous and other disciplines.
His studies deal with areas such as Bioresorbable vascular scaffold, Mace, Everolimus and Bioresorbable scaffold as well as Surgery.
His Stent research is within the category of Radiology.
He most often published in these fields:
- Internal medicine (49.53%)
- Cardiology (44.16%)
- Percutaneous coronary intervention (40.19%)
What were the highlights of his more recent work (between 2018-2021)?
- Percutaneous coronary intervention (40.19%)
- Internal medicine (49.53%)
- Conventional PCI (30.14%)
In recent papers he was focusing on the following fields of study:
His main research concerns Percutaneous coronary intervention, Internal medicine, Conventional PCI, Cardiology and Myocardial infarction.
His work carried out in the field of Percutaneous coronary intervention brings together such families of science as Stent, Clinical endpoint, Randomized controlled trial, Confidence interval and Stroke.
As a part of the same scientific study, he usually deals with the Stent, concentrating on Intravascular ultrasound and frequently concerns with Lesion.
Yoshinobu Onuma studies Internal medicine, focusing on Hazard ratio in particular.
His Conventional PCI research incorporates elements of Coronary artery disease, Ticagrelor, Acute coronary syndrome and Revascularization.
His Cardiology study integrates concerns from other disciplines, such as Subgroup analysis and Cohort.
Between 2018 and 2021, his most popular works were:
- Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications (39 citations)
- Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial (36 citations)
- Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial (36 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Myocardial infarction
The scientist’s investigation covers issues in Percutaneous coronary intervention, Conventional PCI, Randomized controlled trial, Internal medicine and Myocardial infarction.
His Percutaneous coronary intervention research is multidisciplinary, incorporating perspectives in Stent, Stroke, Clinical endpoint, Angiography and Cardiac surgery.
His Stent research includes themes of Intravascular ultrasound, Thrombosis and Nuclear medicine.
His research investigates the connection with Conventional PCI and areas like Drug-eluting stent which intersect with concerns in Standard of care, Biomedical engineering, Stent design and Bioresorbable scaffold.
His studies examine the connections between Randomized controlled trial and genetics, as well as such issues in Regimen, with regards to Stent implantation, Concomitant, Therapy duration and Interventional cardiology.
As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Cardiology, and often Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
